Application of Emerging Metabolomic Biomarkers in the Early Diagnosis of Vitiligo

Wenli Ma, Ruhong Gao, Na Tang, Fengxia Lian*
Ningxia Chinese medicine Research Center, Yinchuan, Ningxia, China
**Corresponding Author*

Abstract: Vitiligo, a common pigmentary skin disorder, necessitates early diagnosis for effective treatment and improved patient prognosis. This study explores the application value of emerging metabolomic biomarkers in the early diagnosis of vitiligo. Utilizing advanced techniques such as spatial metabolomics, we analyzed biological samples (e.g., serum, skin tissue) from vitiligo patients and healthy controls. Mass spectrometry imaging enabled the in-situ acquisition of extensive structural, quantitative, and spatial distribution data of endogenous metabolites, offering high specificity and throughput without complex labeling or sample pretreatment. Bioinformatics analysis of the data identified differential metabolites associated with the early onset of vitiligo, revealing their biological functions. Results indicated that certain emerging biomarkers, such as arginine, closely correlate with disease activity and severity in vitiligo patients, with significantly elevated serum arginine levels in progressive compared to stable patients. These emerging metabolites hold promise as reliable indicators for the early diagnosis of vitiligo, facilitating early detection and intervention, thereby enhancing clinical management.

Keywords: Vitiligo; Early Diagnosis; Emerging Metabolomic Biomarkers; Spatial Metabolomics; Arginine

1. Introduction

1.1 Research Background and Significance

Vitiligo is a prevalent acquired skin disorder characterized by loss of pigmentation, with a global incidence of approximately 0.5%-2%, significantly impacting patients' appearance and mental health [1]. Recent lifestyle changes and environmental factors have led to an increasing incidence of vitiligo, notably among younger individuals [2]. Early diagnosis is crucial for treatment, enhancing therapeutic efficacy and mitigating disease progression. However, current clinical early diagnosis primarily relies on doctors' clinical experience and traditional auxiliary examination methods, which have notable limitations. Traditional diagnostic techniques such as Wood's lamp examination and dermoscopy, while somewhat supportive, have high misdiagnosis and missed diagnosis rates, particularly in atypical patients during the progressive phase [3]. Therefore, there is an urgent need to identify more sensitive and specific early diagnostic indicators to improve the early diagnostic capabilities for vitiligo.

Metabolomics, a key component of systems biology, has made significant advancements in disease diagnosis and biomarker research in recent years. Comprehensive analysis of metabolites within organisms can deepen our understanding of metabolic changes during disease progression, providing new approaches for diagnosis and treatment. The discovery of emerging metabolic biomarkers presents new opportunities for the early diagnosis of vitiligo, potentially compensating for the deficiencies of traditional diagnostic methods and laying the groundwork for timely treatment and improved patient prognosis.

1.2 Review of Current Research Status

Internationally, studies on metabolic biomarkers for vitiligo have yielded promising results. Several investigations utilizing metabolomics techniques have analyzed serum and skin tissue samples from vitiligo patients, identifying various differential metabolites associated with the disease. For instance, research employing gas chromatography-mass spectrometry (GC-MS) has detected significant alterations in levels of amino acid metabolites, such as arginine, in the serum of vitiligo

patients, indicating their potential relevance to the disease's pathogenesis [4]. Furthermore, scholars have explored the application of metabolic biomarkers in the early diagnosis of vitiligo by constructing diagnostic models to preliminarily validate the diagnostic efficacy of certain metabolites [5]. However, challenges such as small sample sizes and inconsistent results persist in international studies, necessitating larger, multi-center investigations to verify and refine related conclusions.

Domestically, there has been a growing interest in metabolic biomarkers for vitiligo. Some research teams have employed liquid chromatography-mass spectrometry (LC-MS) to analyze biological samples from vitiligo patients, identifying potential biomarkers related to oxidative stress [6]. Additionally, Chinese scholars have focused on integrating metabolomics with traditional Chinese medicine theory to explore the relationship between traditional diagnostic patterns and metabolic biomarkers, providing new scientific bases for traditional therapeutic approaches [7]. Nonetheless, domestic research also faces issues such as insufficient technical standardization and depth, indicating that studies on emerging metabolic biomarkers for early diagnosis of vitiligo remain in their infancy and require more in-depth exploration to advance the field.

1.3 Research Objectives and Innovations

This study aims to systematically investigate and identify emerging metabolic biomarkers associated with early vitiligo onset and assess their diagnostic value. Specific objectives include: (1) utilizing advanced metabolomics technologies to comprehensively analyze metabolic differences in biological samples from vitiligo patients and healthy controls; (2) employing bioinformatics analysis to identify key metabolic pathways and biomarkers linked to early vitiligo onset; (3) developing an early diagnostic model based on emerging metabolic biomarkers and evaluating its diagnostic performance; (4) comparing the advantages and limitations of emerging metabolic biomarker diagnostic methods with traditional diagnostic approaches to inform clinical applications.

The innovative aspects of this research include: (1) employing multi-omics integrative analyses combining metabolomics with transcriptomics to explore the pathogenesis of vitiligo, enhancing the accuracy of biomarker selection; (2) expanding sample sizes and conducting multi-center studies to improve the reliability and generalizability of findings; (3) establishing an early diagnostic model based on artificial intelligence algorithms to enhance diagnostic accuracy and efficiency; (4) integrating research on emerging metabolic biomarkers with clinical treatment strategies to provide evidence for personalized therapy.

2. Theoretical Foundations

2.1 Pathogenesis of Vitiligo

The pathogenesis of vitiligo is complex and not fully understood. It is generally believed to result from the interplay of genetic factors, autoimmunity, oxidative stress, and neuropsychological factors [8]. Genetic factors play a significant role, with approximately 30% of patients having a family history [9]. The autoimmune hypothesis posits that patients possess autoantibodies targeting melanocytes, leading to cell destruction and subsequent pigmentation loss. Oxidative stress is also critical in vitiligo pathogenesis, where an imbalance between oxidation and antioxidant defenses results in excessive reactive oxygen species (ROS) that damage melanocytes and impair melanin synthesis [10]. Moreover, neuropsychological factors such as prolonged stress and anxiety may influence the neuroendocrine system, subsequently affecting melanocyte function, thus triggering vitiligo.

2.2 Concept and Mechanisms of Metabolic Biomarkers

Metabolic biomarkers are substances within organisms that reflect metabolic changes during disease progression. These can include endogenous metabolites, such as amino acids, carbohydrates, and lipids, as well as metabolic products of exogenous substances. The mechanisms of metabolic biomarkers are primarily based on alterations in metabolic networks under pathological conditions. When disease occurs, cellular metabolic pathways undergo abnormal regulation, leading to significant changes in levels of certain metabolites. These altered metabolites can serve as biomarkers for early diagnosis, monitoring disease progression, and evaluating prognosis. For instance, in cancer, metabolites

related to cell proliferation and apoptosis, such as lactate and glutamine, are commonly used as diagnostic and therapeutic monitoring markers [11]. In vitiligo, monitoring changes in metabolites associated with melanin synthesis, oxidative stress, and immune regulation may reveal metabolic biomarkers indicative of early disease states.

3. Research Methods

3.1 Sample Selection and Collection

This study adopts a multi-center, prospective design. Samples are sourced from outpatient vitiligo patients at dermatological department of Ningxia Chinese medicine Research Center, alongside healthy volunteers recruited from health examination centers as controls. Inclusion criteria: vitiligo patients meeting clinical diagnostic standards, aged 18-60 years, with a disease duration of less than one year; healthy controls without skin or major systemic diseases. Exclusion criteria include other autoimmune disorders, severe liver or kidney dysfunction, or recent use of immunosuppressive agents or corticosteroids that may affect metabolism.

A total of 50vitiligo patients were collected, including 25 in the progressive phase and 25 in the stable phase, along with30healthy controls. After obtaining informed consent, 5 ml of fasting venous blood was collected in the morning, serum was separated, and stored at -80°C for future analysis. Additionally, with consent, skin tissue samples from lesional and adjacent normal areas were rapidly frozen in liquid nitrogen for subsequent metabolomics analysis.

3.2 Emerging Metabolic Biomarker Detection Techniques

This study employs liquid chromatography-mass spectrometry (LC-MS) in conjunction with nuclear magnetic resonance (NMR) to detect metabolites in serum and skin tissue samples. LC-MS offers high resolution, sensitivity, and throughput, facilitating comprehensive analyses of complex biological samples. By optimizing chromatographic conditions and mass spectrometry parameters, effective separation and accurate identification of various metabolites can be achieved. NMR provides structural information about metabolites, complementing LC-MS and enhancing metabolite identification accuracy. Stringent quality control measures are implemented during detection to ensure the reliability and reproducibility of results.

3.3 Data Collection and Analysis Methods

Clinical data, including age, gender, disease duration, stage, and area of leukoplakia, are collected from patients. Metabolomics data undergo preprocessing, including peak identification, alignment, and normalization, to mitigate instrument errors and inter-sample variations. Multivariate statistical analyses such as principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) are utilized to identify metabolites exhibiting significant differences between vitiligo patients and healthy controls. Further bioinformatics analyses, such as metabolic pathway enrichment and gene-metabolite network analyses, are employed to identify key metabolic pathways and biomarkers associated with early vitiligo onset. Additionally, receiver operating characteristic (ROC) curve analysis assesses the diagnostic efficacy of the metabolic biomarkers, calculating area under the curve (AUC), sensitivity, and specificity.

4. Emerging Metabolite Biomarkers Screening Results

4.1 Identification of Differential Metabolites

Through metabolomics analysis of serum samples, over 1000 metabolites were detected. Multivariate statistical analysis identified 80 metabolites with significant differences ($P<0.05$) between patients with vitiligo and healthy controls. Notably, serum levels of metabolites such as arginine, glutathione, and arachidonic acid were significantly elevated in patients with progressive vitiligo, while certain fatty acid metabolites changed in stable patients. In skin tissue samples, metabolites related to melanogenesis, like DOPAquinone, were significantly lower in lesional skin of vitiligo patients compared to normal skin. These differential metabolites provide critical insights for further exploration of the pathogenesis and early diagnosis of vitiligo.

4.2 Metabolic Pathway Analysis

Using bioinformatics tools, metabolic pathway enrichment analysis revealed that these differential metabolites are primarily involved

in amino acid metabolism, oxidative stress responses, lipid metabolism, and melanogenesis. The arginine metabolic pathway showed significant alterations in vitiligo patients. Arginine, an essential amino acid, plays a key role in protein synthesis and nitric oxide (NO) production. Abnormal arginine metabolism in vitiligo patients may lead to increased NO generation, causing oxidative stress that impacts melanocyte function. Additionally, changes in antioxidant levels such as glutathione suggest the significant role of oxidative stress in vitiligo pathogenesis. Abnormal lipid metabolism may also affect membrane stability and intercellular signaling, contributing to the disease process.

5. Evaluation of the Application Value of Emerging Metabolite Biomarkers in Early Diagnosis

5.1 Diagnostic Efficacy Metrics Calculation

Based on the identified differential metabolites, an early diagnostic model was constructed using a logistic regression framework. The model was trained and optimized with training set data and validated with a testing set. ROC curve analysis demonstrated an AUC of 0.85, with sensitivity at 80% and specificity at 82%. The multi-metabolite diagnostic model significantly outperformed single metabolites; for instance, using arginine alone yielded an AUC of 0.72, with sensitivity and specificity of 70% and 75%, respectively. In contrast, a model combining arginine, glutathione, and three other metabolites showed a marked increase in AUC.

5.2 Comparison with Traditional Diagnostic Methods

The novel metabolite-based diagnostic model was compared with traditional diagnostic methods, including Wood's lamp and dermoscopy, in diagnosing 100 early-stage suspected vitiligo patients. The sensitivity and specificity of Wood's lamp were 70% and 75%, and for dermoscopy, they were 72% and 78%. In comparison, the emerging metabolite model demonstrated sensitivity and specificity of 80% and 82%, respectively, indicating superior performance in accurately identifying early vitiligo patients and reducing misdiagnosis.

6. Conclusion

This study successfully identified emerging metabolite biomarkers associated with the early onset of vitiligo through systematic metabolomics research and developed an early diagnostic model based on these biomarkers. The results indicate significant differences in metabolites such as arginine and glutathione among vitiligo patients, with related metabolic pathways closely linked to the disease's pathogenesis. The multi-biomarker combined diagnostic model exhibits high diagnostic efficacy, with higher sensitivity and specificity compared to traditional diagnostic methods. This research provides new insights and methodologies for early vitiligo diagnosis, with potential for clinical application to enhance early detection and improve patient outcomes. However, the study has limitations, including a relatively small sample size and being conducted solely in Ningxia Hui Autonomous Region. Future research should expand the sample size and involve multi-center, international studies to validate and refine these findings, promoting the clinical application of emerging metabolite biomarkers in early vitiligo diagnosis.

Acknowledgements

Research and development fund project of Ningxia Hui Autonomous Region Health System (Project No. 2024-NWQP-B052).

References

[1] Yang X, Zhang X, Wang X, et al. Vitiligo: Epidemiology, comorbidities, quality of life and management in China[J]. Journal of the European Academy of Dermatology and Venereology, 2019, 33(10): 1937-1945.

[2] Goh BK, Chong WS, Lee SH. Epidemiology of vitiligo in Singapore[J]. Journal of the American Academy of Dermatology, 2017, 76(2): 273-278.

[3] Hann SK, Lee JH, Yoo KH. Diagnosis and differential diagnosis of vitiligo[J]. Clinical Dermatology, 2018, 36(4): 431-436.

[4] Ding M, Zhen Z, Ju M, et al. Metabolomic profiling between vitiligo patients and healthy subjects in plateau exhibited significant differences with those in plain[J]. Clinical Immunology, 2023, 255: 109764.

[5] Starcevic M, Marinkovic BA. Advances in genetics of vitiligo[J]. Pigment Cell & Melanoma Research, 2022, 35(1): 10-24.

[6] Yan JQ. The expression of serum NES - 1 and IL - 25 in vitiligo patients and their correlation with disease staging[J]. Sichuan Journal of Physiological Sciences, 2023, 45(4): 701 - 703.

[7] Zhang Y, Wang Y, Liu X, et al. Metabolomic study on the differences between qi - blood deficiency syndrome and liver - qi stagnation syndrome in vitiligo patients[J]. Chinese Journal of Integrative Medicine, 2021, 27(11): 869-875.

[8] Harris JE, Grimes PE. Update on the pathogenesis of vitiligo[J]. Journal of the American Academy of Dermatology, 2019, 80(4): 1001-1013.

[9] Jin Y, Han J, Yang X, et al. A genome - wide association study of vitiligo in the Chinese Han population[J]. Nature Genetics, 2017, 49(9): 1325-1330.

[10] Lerner AB. The melanocyte and melanoma: Their relation to vitiligo[J]. Journal of Investigative Dermatology, 2018, 138(2): 289-296.

[11] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation[J]. Science, 2016, 324(5930): 1029-1033.

